{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T01:13:14Z","timestamp":1778980394138,"version":"3.51.4"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cross-sectional study investigates the growth in the number of clinicians in the US who obtained waivers for prescribing buprenorphine after the elimination of federal educational requirements.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2022.37912","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T15:30:43Z","timestamp":1666366243000},"page":"e2237912","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of US County Characteristics and Clinicians With Waivers to Prescribe Buprenorphine After Changes in Federal Education Requirements"],"prefix":"10.1001","volume":"5","author":[{"given":"Thuy","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Andraka-Christou","sequence":"additional","affiliation":[{"name":"School of Global Health Management and Informatics, University of Central Florida, Orlando"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Arnaudo","sequence":"additional","affiliation":[{"name":"Indiana University Health, Bloomington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. David","family":"Bradford","sequence":"additional","affiliation":[{"name":"Department of Public Administration and Policy, University of Georgia, Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosali","family":"Simon","sequence":"additional","affiliation":[{"name":"O\u2019Neil School of Public and Environmental Affairs, Indiana University, Bloomington"},{"name":"National Bureau of Economic Research, Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Spetz","sequence":"additional","affiliation":[{"name":"Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"9","key":"zld220242r1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"zld220242r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.5996","article-title":"Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements.","volume":"5","author":"Spetz","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zld220242r5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/jrh.v38.1","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.","volume":"38","author":"Andrilla","year":"2022","journal-title":"J Rural Health"},{"issue":"12","key":"zld220242r6","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1377\/hlthaff.2019.00859","article-title":"In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants.","volume":"38","author":"Barnett","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"zld220242r2","unstructured":"US Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. April 28, 2021. Accessed May 30, 2022. https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder"},{"key":"zld220242r4","unstructured":"Ahmad? F, Rossen? L, Sutton? P. Provisional drug overdose death counts. Reviewed August 18, 2022. Accessed August 30, 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797551\/nguyen_2022_ld_220242_1665672311.35588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T15:30:45Z","timestamp":1666366245000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":6,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.37912","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}